ODONATE, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18,810 USD | +10.00% |
|
+18.30% | +25.40% |
| 2023 | North American Morning Briefing : Recession Threat Grows as Further Tightening Likely | DJ |
| 2023 | North American Morning Briefing : Stock Futures -2- | DJ |
Financials (USD)
| Sales 2019 | - | Sales 2020 | - | Capitalization | 740M |
|---|---|---|---|---|---|
| Net income 2019 | -112M | Net income 2020 | -126M | EV / Sales 2019 | - |
| Net cash position 2019 | 178M | Net cash position 2020 | 152M | EV / Sales 2020 | - |
| P/E ratio 2019 * |
-
| P/E ratio 2020 |
-
| Employees | 145 |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +10.00% | ||
| 1 week | +18.30% | ||
| Current month | +7.49% | ||
| 1 month | +11.30% | ||
| 3 months | +32.00% | ||
| 6 months | +25.40% | ||
| Current year | +25.40% |
1 week
17 100.00
18 810.00
1 month
15 400.0018 810.00
Current year
13 625.0049 895.00
1 year
13 625.0049 895.00
3 years
8 077.0049 895.00
5 years
8 077.00464 999.00
10 years
8 077.00464 999.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Tang
CEO | Chief Executive Officer | 57 | 12-12-31 |
Michael Hearne
DFI | Director of Finance/CFO | 61 | 14-12-31 |
Ryan Cole
COO | Chief Operating Officer | - | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kevin Tang
CEO | Chief Executive Officer | 57 | 12-12-31 |
Craig Johnson
BRD | Director/Board Member | 62 | 17-06-30 |
Aaron Davis
BRD | Director/Board Member | 45 | 16-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 18,810 | +10.00% | 1 |
| 24-04-22 | 17,100 | -0.71% | 4 |
| 24-04-19 | 17,222 | +8.32% | 1 |
Delayed Quote OTC Markets, April 25, 2024 at 02:44 pm EDT
More quotes
Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +25.40% | 53.42M | |
| +25.40% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +12.98% | 233B | |
| +5.31% | 201B | |
| -9.98% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- ODT Stock
